Disrupt CAD III With the Shockwave Coronary IVL System

Coronary Artery Disease Clinical Trial

Official title:

Prospective, Multicenter, Single-Arm, Global IDE Study of the Shockwave Coronary Intravascular Lithotripsy (IVL) System With the Shockwave C2 Coronary IVL Catheter in Calcified Coronary Arteries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03595176
• Other study ID #: CP 61982
• Status: Completed
• Phase: N/A
• Start date: January 9, 2019
• Est. completion date: April 10, 2022

Study information

• Verified date: May 2023
• Source: Shockwave Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries prior to stenting. Disrupt CAD III is being conducted as a staged pivotal study.

Description:

Subject Population: Subjects ≥ 18 years of age with de novo, calcified coronary artery lesions presenting with stable, unstable or silent ischemia that are suitable for percutaneous coronary intervention (PCI). Approximately 392 subjects at 50 sites will be enrolled. A minimum of 50% of the total enrollment will come from the United States.Subjects will be followed through discharge, 30 days, 6, 12 and 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 431
• Est. completion date: April 10, 2022
• Est. primary completion date: May 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Subject is =18 years of age

2. Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for PCI

3. For patients with unstable ischemic heart disease, biomarkers (troponin or CK-MB) must be less than or equal to the upper limit of lab normal within 12 hours prior to the procedure (note: if both labs are drawn, both must be normal).

4. For patients with stable ischemic heart disease, biomarkers may be drawn prior to the procedure or at the time of the procedure from the side port of the sheath.

1. If drawn prior to the procedure, biomarkers (troponin or CK-MB) must be less than or equal to the upper limit of lab normal within 12 hours of the procedure (note: if both labs are drawn, both must be normal).

2. If biomarkers are drawn at the time of the procedure from the side port of the sheath prior to any intervention, biomarker results do not need to be analyzed prior to enrollment (note: CK-MB is required if drawn from the sheath).

5. Left ventricular ejection fraction >25% within 6 months (note: in the case of multiple assessments of LVEF, the measurement closest to enrollment will be used for this criteria; may be assessed at time of index procedure)

6. Subject or legally authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures

7. Lesions in non-target vessels requiring PCI may be treated either:

1. >30 days prior to the study procedure if the procedure was unsuccessful or complicated; or

2. >24 hours prior to the study procedure if the procedure was successful and uncomplicated (defined as a final lesion angiographic diameter stenosis <30% and TIMI 3 flow (visually assessed) for all non-target lesions and vessels without perforation, cardiac arrest or need for defibrillation or cardioversion or hypotension/heart failure requiring mechanical or intravenous hemodynamic support or intubation, and with no post-procedure biomarker elevation >normal; or

3. >30 days after the study procedure

Angiographic Inclusion Criteria

8. The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure

9. Single de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of their branches) with:

1. Stenosis of =70% and <100% or

2. Stenosis =50% and <70% (visually assessed) with evidence of ischemia via positive stress test, or fractional flow reserve value =0.80, or iFR <0.90 or IVUS or OCT minimum lumen area =4.0 mm²

10. The target vessel reference diameter must be =2.5 mm and =4.0 mm

11. The lesion length must not exceed 40 mm

12. The target vessel must have TIMI flow 3 at baseline (visually assessed; may be assessed after pre- dilatation)

13. Evidence of calcification at the lesion site by, a) angiography, with fluoroscopic radio-opacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, OR by b) IVUS or OCT, with presence of =270 degrees of calcium on at least 1 cross section

14. Ability to pass a 0.014" guide wire across the lesion

Exclusion Criteria:

1. Any comorbidity or condition which may reduce compliance with this protocol, including follow-up visits

2. Subject is a member of a vulnerable population as defined in 21 CFR 56.111, including individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention

3. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint

4. Subject is pregnant or nursing (a negative pregnancy test is required for women of child-bearing potential within 7 days prior to enrollment)

5. Unable to tolerate dual antiplatelet therapy (i.e., aspirin, and either clopidogrel, prasugrel, or ticagrelor) for at least 6 months (for patients not on oral anticoagulation)

6. Subject has an allergy to imaging contrast media which cannot be adequately pre-medicated

7. Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure, defined as a clinical syndrome consistent with an acute coronary syndrome with troponin or CK-MB greater than 1 times the local laboratory's upper limit of normal

8. New York Heart Association (NYHA) class III or IV heart failure

9. Renal failure with serum creatinine >2.5 mg/dL or chronic dialysis

10. History of a stroke or transient ischemic attack (TIA) within 6 months, or any prior intracranial hemorrhage or permanent neurologic deficit

11. Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months

12. Untreated pre-procedural hemoglobin <10 g/dL or intention to refuse blood transfusions if one should become necessary

13. Coagulopathy, including but not limited to platelet count <100,000 or International Normalized ratio (INR) > 1.7 (INR is only required in subjects who have taken warfarin within 2 weeks of enrollment)

14. Subject has a hypercoagulable disorder such as polycythemia vera, platelet count >750,000 or other disorders

15. Uncontrolled diabetes defined as a HbA1c greater than or equal to 10%

16. Subject has an active systemic infection on the day of the index procedure with either fever, leukocytosis or requiring intravenous antibiotics

17. Subjects in cardiogenic shock or with clinical evidence of left-sided heart failure (S3 gallop, pulmonary rales, oliguria, or hypoxemia)

18. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)

19. Subjects with a life expectancy of less than 1 year

20. Non-coronary interventional or surgical structural heart procedures (e.g., TAVR, MitraClip, LAA or PFO occlusion, etc.) within 30 days prior to the index procedure

21. Planned non-coronary interventional or surgical structural heart procedures (e.g., TAVR, MitraClip, LAA or PFO occlusion, etc.) within 30 days after the index procedure

22. Subject refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery

23. Planned use of atherectomy, scoring or cutting balloon, or any investigational device other than lithotripsy

24. High SYNTAX Score (=33) if assessed as standard of care, unless the local heart team has met and recommends PCI is the most appropriate treatment for the patient

25. Unprotected left main diameter stenosis >30%

26. Target vessel is excessively tortuous defined as the presence of two or more bends >90º or three or more bends >75º

27. Definite or possible thrombus (by angiography or intravascular imaging) in the target vessel

28. Evidence of aneurysm in target vessel within 10 mm of the target lesion

29. Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion

30. Target lesion is a bifurcation with ostial diameter stenosis =30%

31. Second lesion with >50% stenosis in the same target vessel as the target lesion including its side branches

32. Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft

33. Previous stent within the target vessel implanted within the last year

34. Previous stent within 10 mm of the target lesion regardless of the timing of its implantation

35. Angiographic evidence of a dissection in the target vessel at baseline or after guidewire passage

Related Conditions & MeSH terms

• Coronary Artery Disease
• Infarction
• Myocardial Infarction

Intervention

Device:
• Lithotripsy
Deliver Lithotripsy to the target vessel prior to placing a coronary stent.

Locations

Country	Name	City	State
France	Clinique des Domes - Pole Sante Republique	Clermont-Ferrand
France	Institute Cardiovasculaire Paris Sud	Massy
France	Clinique Pasteur	Toulouse	Cedex 3
Germany	Charité - Universitaetsmedizin Berlin	Berlin
Germany	Universitaetsklinikum Giessen and Marburg GmbH	Marburg	CET
Germany	Rheinland Klinikum Neuss GmbH - Lukaskrankenhaus Neuss	Neuss
United Kingdom	Golden Jubilee National Hospital	Clydebank
United Kingdom	King's College Hospital	London
United Kingdom	St. Bartholomew's Hospital	London
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Piedmont Heart Institute	Atlanta	Georgia
United States	MedStar Union Memorial Hospital	Baltimore	Maryland
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	Deborah Heart and Lung Center	Browns Mills	New Jersey
United States	Bryn Mawr Hospital	Bryn Mawr	Pennsylvania
United States	University of Vermont	Burlington	Vermont
United States	Charleston Area Medical Center (CAMC) - Health Education & Research Institute	Charleston	West Virginia
United States	Northwestern University	Chicago	Illinois
United States	The Christ Hospital	Cincinnati	Ohio
United States	Baylor Heart and Vascular Hospital	Dallas	Texas
United States	Geisinger Medical Center	Danville	Pennsylvania
United States	Henry Ford Hospital	Detroit	Michigan
United States	Durham VA Health Care System	Durham	North Carolina
United States	Houston Methodist Hospital	Houston	Texas
United States	St. Vincent Heart Center of Indiana, LLC	Indianapolis	Indiana
United States	Saint Luke's Hospital of Kansas City	Kansas City	Missouri
United States	Scripps Clinic	La Jolla	California
United States	University of California, San Diego (UCSD) - Medical Center	La Jolla	California
United States	Minneapolis Heart Institute	Minneapolis	Minnesota
United States	Yale New Haven Hospital	New Haven	Connecticut
United States	Ochsner Clinic Foundation	New Orleans	Louisiana
United States	Columbia University Medical Center/ New York Presbyterian	New York	New York
United States	New York University (NYU) Langone Medical Center	New York	New York
United States	Advocate Health and Hospitals Corporation - Edward Hospital	Oakbrook Terrace	Illinois
United States	St. Joseph Hospital	Orange	California
United States	VA Palo Alto Health Care System	Palo Alto	California
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	The Miriam Hospital	Providence	Rhode Island
United States	NC Heart and Vascular	Raleigh	North Carolina
United States	St. Francis Hospital	Roslyn	New York
United States	Honor Health	Scottsdale	Arizona
United States	University of Washington Medical Center	Seattle	Washington
United States	North Mississippi Medical Center	Tupelo	Mississippi
United States	MedStar Washington Hospital Center	Washington	District of Columbia
United States	Pinnacle Health Cardiovascular Institute Inc.	Wormleysburg	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Shockwave Medical, Inc.

Countries where clinical trial is conducted

United States,  France,  Germany,  United Kingdom, 

References & Publications (2)

Hill JM, Kereiakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW; Disrupt CAD III Investigators. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. J Am Coll Cardiol. 2020 — View Citation

Kereiakes DJ, Hill JM, Ben-Yehuda O, Maehara A, Alexander B, Stone GW. Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial. Am He — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure	The primary safety endpoint was freedom from MACE at 30 days - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR). The primary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Primary	Number of Participants With Procedural Success (Residual Stenosis <50%)	The primary effectiveness endpoint was Procedural Success defined as stent delivery with a residual in-stent stenosis <50% (core laboratory assessed) and without in-hospital MACE. The primary endpoints were analyzed using the Pivotal Analysis Set.	12-24 hours post procedure or at discharge, whichever is earlier, but at least 6 hours post procedure
Secondary	Number of Participants With Device Crossing Success	Device Crossing Success defined as the ability to deliver the IVL catheter across the target lesion, and delivery of lithotripsy without serious angiographic complications immediately after IVL. The secondary endpoints were analyzed using the Pivotal Analysis Set.	at end of procedure
Secondary	Number of Participants With Angiographic Success (Residual Stenosis <50%)	Angiographic Success defined as stent delivery with <50% residual stenosis and without serious angiographic complications. The secondary endpoints were analyzed using the Pivotal Analysis Set.	at end of procedure
Secondary	Number of Participants With Procedural Success (Residual Stenosis <=30%)	Procedural Success defined as stent delivery with a residual stenosis <=30% (core laboratory assessed) and without in-hospital MACE. The secondary endpoints were analyzed using the Pivotal Analysis Set.	12-24 hours post procedure or at discharge, whichever is earlier, but at least 6 hours post procedure
Secondary	Number of Participants With Angiographic Success (Residual Stenosis <=30%)	Angiographic Success defined as stent delivery with <=30% residual stenosis and without serious angiographic complications. The secondary endpoints were analyzed using the Pivotal Analysis Set.	at end of procedure
Secondary	Number of Participants With Serious Angiographic Complications	Serious Angiographic Complications defined as severe dissection (Type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow. The secondary endpoints were analyzed using the Pivotal Analysis Set.	at end of procedure
Secondary	MACE Rate at 6 Months	MACE at 6 months - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR) - is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	MACE Rate at 12 Months	MACE at 12 months - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR) - is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	MACE Rate at 24 Months	MACE at 24 months - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR) - is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Target Lesion Failure (TLF) Rate at 30 Days	Target lesion failure (TLF) is defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods. 30 day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Target Lesion Failure (TLF) Rate at 6 Months	TLF is defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods. For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Target Lesion Failure (TLF) Rate at 12 Months	TLF is defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods. For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Target Lesion Failure (TLF) Rate at 24 Months	TLF is defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods. For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	All-Cause Death Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	All-Cause Death Rate at 6 Months	All-cause death at 6 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	All-Cause Death Rate at 12 Months	All-cause death at 12 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	All-Cause Death Rate at 24 Months	All-cause death at 24 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Cardiac Death Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Cardiac Death Rate at 6 Months	Cardiac death at 6 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Cardiac Death Rate at 12 Months	Cardiac death at 12 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Cardiac Death Rate at 24 Months	Cardiac death at 24 months is presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	MI Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	MI Rate at 6 Months	MI is presented as a Kaplan-Meier estimated event rate at 6 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	MI Rate at 12 Months	MI is presented as a Kaplan-Meier estimated event rate at 12 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	MI Rate at 24 Months	MI is presented as a Kaplan-Meier estimated event rate at 24 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Target Vessel-Myocardial Infarction (TV-MI) Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	TV-MI Rate at 6 Months	TV-MI is presented as a Kaplan-Meier estimated event rate at 6 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	TV-MI Rate at 12 Months	TV-MI is presented as a Kaplan-Meier estimated event rate at 12 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	TV-MI Rate at 24 Months	TV-MI is presented as a Kaplan-Meier estimated event rate at 24 months. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Procedural MI Rate at 30 Days	Periprocedural MI defined as CK-MB > 3x upper limit of lab normal (ULN). 30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Procedural MI Rate at 6 Months	Periprocedural MI defined as CK-MB > 3x upper limit of lab normal (ULN). For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Procedural MI Rate at 12 Months	Periprocedural MI defined as CK-MB > 3x upper limit of lab normal (ULN). For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Procedural MI Rate at 24 Months	Periprocedural MI defined as CK-MB > 3x upper limit of lab normal (ULN). For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Non-Procedural MI Rate at 30 Days	Non-Procedural MI defined as spontaneous MI beyond discharge (4th Universal Definition). 30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Non-Procedural MI Rate at 6 Months	Non-Procedural MI defined as spontaneous MI beyond discharge (4th Universal Definition). For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Non-Procedural MI Rate at 12 Months	Non-Procedural MI defined as spontaneous MI beyond discharge (4th Universal Definition). For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Non-Procedural MI Rate at 24 Months	Non-Procedural MI defined as spontaneous MI beyond discharge (4th Universal Definition). For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Ischemia-Driven Target Vessel Revascularization (ID-TVR) Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	ID-TVR Rate at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	ID-TVR Rate at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	ID-TVR Rate at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Ischemia-Driven Target Lesion Revascularization (ID-TLR) Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	ID-TLR Rate at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	ID-TLR Rate at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	ID-TLR Rate at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Non-ID-TVR Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Non-ID-TVR Rate at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Non-ID-TVR Rate at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Non-ID-TVR Rate at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Non-ID-TLR Rate at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Non-ID-TLR Rate at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Non-ID-TLR Rate at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Non-ID-TLR Rate at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Any Revascularizations Rate at 30 Days	Any revascularizations (ID and non-ID) at 30 days. 30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Any Revascularizations Rate at 6 Months	Any revascularizations (ID and non-ID) at 6 months, presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Any Revascularizations Rate at 12 Months	Any revascularizations (ID and non-ID) at 12 months, presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Any Revascularizations Rate at 24 Months	Any revascularizations (ID and non-ID) at 24 months, presented as a Kaplan-Meier estimated event rate. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Stent Thrombosis Rate at 30 Days	Any stent thrombosis (definite, probable, definite or probable) according to Academic Research Consortium (ARC) criteria, as referenced from Cutlip, D.E. et al. Clinical End Points in Coronary Stent Trials. Circ. 2007.115.2344-51. 30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Stent Thrombosis Rate at 6 Months	Any stent thrombosis (definite, probable, definite or probable) according to Academic Research Consortium (ARC) criteria, as referenced from Cutlip, D.E. et al. Clinical End Points in Coronary Stent Trials. Circ. 2007.115.2344-51. For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Stent Thrombosis Rate at 12 Months	Any stent thrombosis (definite, probable, definite or probable) according to Academic Research Consortium (ARC) criteria, as referenced from Cutlip, D.E. et al. Clinical End Points in Coronary Stent Trials. Circ. 2007.115.2344-51. For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Stent Thrombosis Rate at 24 Months	Any stent thrombosis (definite, probable, definite or probable) according to Academic Research Consortium (ARC) criteria, as referenced from Cutlip, D.E. et al. Clinical End Points in Coronary Stent Trials. Circ. 2007.115.2344-51. For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Rate of MI Using the 4th Universal Definition at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Rate of MI Using the 4th Universal Definition at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Rate of MI Using the 4th Universal Definition at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Rate of MI Using the 4th Universal Definition at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure
Secondary	Rate of MI Using the Society for Cardiovascular Angiography and Interventions (SCAI) Definition at 30 Days	30-day rates are presented as proportions. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 30 days of index procedure
Secondary	Rate of MI Using the SCAI Definition at 6 Months	For 6 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 6 months of index procedure
Secondary	Rate of MI Using the SCAI Definition at 12 Months	For 12 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 12 months of index procedure
Secondary	Rate of MI Using the SCAI Definition at 24 Months	For 24 months, rates are presented as Kaplan-Meier estimated event rates. The secondary endpoints were analyzed using the Pivotal Analysis Set.	within 24 months of index procedure

External Links

•   Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study